Recursion Pharmaceuticals (NASDAQ: RXRX) insider transactions
In the twelve months to 10 November 2026, executives and directors of Recursion Pharmaceuticals reported 35 open-market sales of 1,904,811 shares ($7.6m) and 0 open-market purchases, by 6 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 3 November 2026 | Borgeson Blake | Director | Open-market sale, 10b5-1 plan | −40,000 | $3.88 | 6,068,287 | Form 4 |
| 2 November 2026 | Hassan Fred | Director | Grant or award | +156,658 | — | 156,658 | Form 4 |
| 6 October 2026 | Hershberg Robert | Director | Option exercise, 10b5-1 plan | +25,000 | $2.22 | 187,156 | Form 4 |
| 6 October 2026 | Hershberg Robert | Director | Open-market sale, 10b5-1 plan | −25,000 | $5.00 | 162,156 | Form 4 |
| 6 October 2026 | Borgeson Blake | Director | Open-market sale, 10b5-1 plan | −50,000 | $4.84 | 6,108,287 | Form 4 |
| 1 October 2026 | Li Dean Y | Director | Grant or award | +3,378 | — | 1,476,707 | Form 4 |
| 1 October 2026 | Dar Zavain | Director | Grant or award | +4,607 | — | 245,371 | Form 4 |
| 15 September 2026 | Taylor Ben R | Chief Financial Officer | Shares withheld for tax | −5,396 | $3.41 | 1,071,462 | Form 4 |
| 8 September 2026 | Khan Najat | CEO and President | Open-market sale, 10b5-1 plan | −22,408 | $3.52 | 2,072,890 | Form 4 |
| 1 September 2026 | Borgeson Blake | Director | Open-market sale, 10b5-1 plan | −30,000 | $3.34 | 6,158,287 | Form 4 |
| 17 August 2026 | Taylor Ben R | Chief Financial Officer | Shares withheld for tax | −25,018 | $3.16 | 1,076,858 | Form 4 |
| 17 August 2026 | Hallett David | Chief Scientific Officer | Shares withheld for tax | −26,657 | $3.16 | 1,043,837 | Form 4 |
| 17 August 2026 | Khan Najat | CEO and President | Shares withheld for tax | −80,498 | $3.16 | 2,095,298 | Form 4 |
| 4 August 2026 | Borgeson Blake | Director | Open-market sale, 10b5-1 plan | −30,000 | $3.25 | 6,188,287 | Form 4 |
| 7 July 2026 | Borgeson Blake | Director | Open-market sale, 10b5-1 plan | −40,000 | $3.96 | 6,218,287 | Form 4 |
| 1 July 2026 | Li Dean Y | Director | Grant or award | +3,747 | — | 1,473,329 | Form 4 |
| 1 July 2026 | Dar Zavain | Director | Grant or award | +5,109 | — | 240,764 | Form 4 |
| 18 June 2026 | Bumpus Namandje | Director | Open-market sale, 10b5-1 plan | −3,963 | $3.18 | 127,632 | Form 4 |
| 17 June 2026 | Bumpus Namandje | Director | Grant or award, 10b5-1 plan | +88,424 | — | 131,595 | Form 4 |
| 17 June 2026 | Li Dean Y | Director | Grant or award | +88,424 | — | 1,469,582 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Recursion Pharmaceuticals page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.